base-metals-investing Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer's Disease Conference
base-metals-investing Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer's Disease Conference
base-metals-investing Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
base-metals-investing Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
base-metals-investing Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
base-metals-investing Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer's Disease
Tartisan Nickel Corp. Appoints Jack Jacobs, Congressional Medal of Honour Recipient, Retired Army Colonel and Distinguished Business Executive to Board of Advisors
